RxDoctor Payments Data

Kanwar Mahal, MD

Internal Medicine · Fresno, CANPI 1154455806

Payments from drug & device makers

$7,713in general payments, 2019–2025

Across 403 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$740
  • Amgen$680
  • Lilly USA, LLC$571
  • GSK$460
  • Pfizer$429
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,707100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,713 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$310,096
Medicare patients
543
Services billed
6,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$78,896
JanuviaSitagliptin Phosphate33$49,513
FarxigaDapagliflozin Propanediol34$46,123
TrulicityDulaglutide22$38,012
JardianceEmpagliflozin20$35,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,625
EliquisApixaban27$29,401
TradjentaLinagliptin20$28,696
MounjaroTirzepatide16$15,036
VascepaIcosapent Ethyl23$11,288
Fluticasone Propionate HfaFluticasone Propionate12$6,094
Icosapent Ethyl11$5,043
Fenofibrate117$3,662
Bupropion XlBupropion Hcl91$3,417
Levothyroxine Sodium263$2,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$250$78,89664 claims
Boehringer IngelheimJardiance, Tradjenta$156$64,16240 claims
Lilly USA, LLCTrulicity, Mounjaro$571$53,04938 claims
MerckJanuvia$77$49,51333 claims
AstraZenecaFarxiga$740$46,12334 claims
GSKTrelegy Ellipta$460$29,62531 claims
PfizerEliquis$429$29,40127 claims
AbbVieSynthroid$1,499$2,54730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →